Anson Funds Management’s Soleno Therapeutics SLNO Stock Holding History

Anson Funds Management’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-44,231	Closed	-$1.48M	–	200
2026 Q1	$1.48M	Buy	+44,231	New	+$1.73M	0.13%	95
2017 Q1	–	Sell	-4,740	Closed	-$288K	–	76
2016 Q4	$288K	Buy	+4,740	New	+$328K	0.09%	57

Anson Funds Management's SLNO Position: Q2 2026 in Review

Anson Funds Management sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 44,231 shares — an estimated $1.48M sold.

Anson Funds Management first reported a position in SLNO in Q4 2016 and held it in 2 quarters. The position peaked at $1.48M in Q1 2026. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

Anson Funds Management reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
Anson Funds Management sold 44,231 Soleno Therapeutics shares in Q2 2026, an estimated $1.48M.
Anson Funds Management first reported a position in Soleno Therapeutics in Q4 2016 and held it in 2 quarters.
Anson Funds Management's Soleno Therapeutics position peaked at $1.48M in Q1 2026.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Anson Funds Management's 13F filing for Q2 2026, filed 13 Aug 2026.